Israel - English - Ministry of Health

megapharm ltd - bleomycin sulfate - powder for solution for injection - bleomycin sulfate 15000 iu/vial - bleomycin - bleomycin - bleomycin is useful in the management of the following neoplasms: squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. well differentiated tumors usually respond better than anaplastic ones.hodgkin's disease and other malignant lymphomas, including mycosis fungoides. testicular carcinoma (seminoma and no seminoma) .malignant effusions of serous cavities (intrapleural and intraperitoneal).secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. local treatment of refractory warts. bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 15 [usp'u] - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. hodgkin's disease, non-hodgkin's lymphoma. embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection has also been shown to be useful in the management of: bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 30 [usp'u] - bleomycin for injection, usp should be considered a palliative treatment.  it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva.  the response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin’s disease, non-hodgkin’s lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha

United States - English - NLM (National Library of Medicine)

hospira, inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 30 [usp'u] - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. lymphomas hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin has also been shown to be useful in the management of: malignant pleural effusion bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 15 [usp'u] - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin is poorer in patients with previously irradiated head and neck cancer. hodgkin's disease, non-hodgkin's lymphoma. embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin 15000 [iu] - palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: - squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). - squamous cell carcinoma of the larynx, penis and uterine cervix. - squamous cell carcinoma of the bronchus (response infrequent). - ch0riocarcinoma and embryonal cell carcinoma of the testis. - advanced hodgkin’s disease and other lymphomas. - mycosis fungoides. note . use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.

Kenya - English - Pharmacy and Poisons Board

bleomycin sulfate usp - injection - bleomycin sulfate usp – 15units/vial - bleomycin

Canada - English - Health Canada

sandoz canada incorporated - bleomycin (bleomycin sulfate) - powder for solution - 15unit - bleomycin (bleomycin sulfate) 15unit - antineoplastic agents

United States - English - NLM (National Library of Medicine)

meitheal pharmaceuticals inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection, usp is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection, usp is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha

United States - English - NLM (National Library of Medicine)

northstar rx llc - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection, usp should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection, usp is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection, usp has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection, usp is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who ha